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Abstract
Background: Tumor-derived autophagosome vaccines (DRibbles) have the potential to broaden immune response
to poorly immunogenic tumors.
Methods: Autologous vaccine generated from tumor cells harvested from pleural effusions was administered to
patients with advanced NSCLC with the objectives of assessing safety and immune response. Four patients were
vaccinated and evaluable for immune response; each received two to four doses of vaccine. Study therapy included two
cycles of docetaxel 75 mg/m2 on days 1 and 29 to treat the tumor, release hidden antigens and produce lymphopenia.
DRibbles were to be administered intradermally on days 14, 43, 57, 71, and 85, together with GM-CSF (50 μg/d x 6d,
administered via SQ mini pump). Peripheral blood was tested for immune parameters at baseline and at each vaccination.
Results: Three of four patients had tumor cells available for testing. Autologous tumor-specific immune response was
seen in two of the three, manifested by IL-5 (1 patient after 3 doses), and IFN-γ, TNF-α, IL-5, IL-10 (after 4 doses in one
patient). All 4 patients had evidence of specific antibody responses against potential tumor antigens. All patients came off
study after 4 or fewer vaccine treatments due to progression of disease. No significant immune toxicities were seen
during the course of the study.
Conclusions: DRibble vaccine given with GM-CSF appeared safe and capable of inducing an immune response against
tumor cells in this small, pilot study. There was no evidence of efficacy in this small poor-prognosis patient population,
with treatment not feasible. Trial registration NCT00850785, initial registration date February 23, 2009.
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Background
Non-small cell lung cancer (NSCLC) is the leading can-
cer killer worldwide [1]. Most patients with NSCLC have
advanced disease, and, despite recent advances in tar-
geted and immune therapies, the goals of treatment are
often palliative. Average survival for patients without
driver mutations is still less than 2 years, and ultimately
most patients will progress due to resistance to available
therapies [2–4].
Failure of the immune system to recognize and destroy
cancer cells may be a cause of cancer development and
progression [5].Clinical trials with antibodies to the pro-
grammed cell death receptor-1 (PD-1), or its ligand, PD-
L1, have demonstrated responses and improved disease
control for patients with advanced and heavily-
pretreated NSCLC [6], resulting in long-term survival
for a small proportion of patients [7]. Although the ma-
jority of patients will not respond to checkpoint
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inhibition, results of these and other studies have led to
FDA approval for checkpoint inhibitors for the treat-
ment of advanced NSCLC, both in the first line setting,
and after progression on platinum-based chemotherapy.
NSCLC without driver mutations is one of the most
heavily mutated of human cancers [8], thus it is likely
that NSCLC cells harbor neoantigens to which the host
would not be tolerant, and against which the immune
system could mount a strong, destructive immune re-
sponse. Despite this, 50% of patients with the highest
number of mutations still progress by 16 months [9].
This observation underscores the point that the tumor-
bearing host may not provide an appropriate environ-
ment to prime anticancer immunity. Expression of
neoantigens alone is insufficient without cross-
presentation by antigen presenting cells in the appropri-
ate cytokine milieu. In addition to mutated proteins,
NSCLC can over-express a number of non-mutated pro-
teins that can induce both humoral and cytotoxic T cell
responses [10], and also have the potential to serve as
tumor rejection antigens [11].
This study was designed to test a novel immunother-
apy strategy using a vaccine enriched for short-lived pro-
teins (SLiPs) and defective ribosomal products (DRiPs)
derived from autologous tumor cells.
Tumor cells were cultured in vitro with the prote-
asome inhibitor bortezomib, which stabilizes SLiPs and
DRiPs, shunting proteins into the autophagy pathway
[12]. After inhibiting lysosomal degradation, SLiPs and
DRiPs accumulate in autophagosomes (“DRiPs in blebs”;
or DRibbles) [13]. Because SLiPs are not normally avail-
able to be cross-presented by APCs, we hypothesized
that there would be less peripheral tolerance against
SLiPs and DRiPs, and, it would thus be easier to induce
immunity against them [12, 14]. Furthermore, because
they are rapidly degraded by the proteasome, peptides
derived from SLiPs and DRiPs would be picked up by
class I molecules in the endoplasmic reticulum and
would comprise the dominant epitopes presented by the
MHC/HLA [13]. Vaccination with DRibbles in preclin-
ical mouse models induced tumor-specific T cells and
provided both protective and therapeutic anti-cancer im-
munity [15, 16].
Docetaxel improves survival and quality of life for pa-
tients with advanced NSCLC that have progressed after
first-line therapy [17]. Docetaxel also produces lympho-
penia [18, 19], which was shown to improve the thera-
peutic effect of vaccine plus GM-CSF, possibly by
increasing exposure to tumor antigens during homeo-
static recovery [20]. Granulocyte-Monocyte colony
stimulating factor (GM-CSF)-gene modified tumor vac-
cines show augmented development of tumor-specific T
cells in preclinical models [21] and demonstrated some
efficacy in early clinical trials in patients with NSCLC
[22]. We have previously reported the use of mini-
pumps to provide continuous infusion of low-dose GM-
CSF to the autologous NSCLC tumor cell vaccine site as
an alternative to gene modification [23] and employed
that strategy here.
Methods
Study design and entry criteria
This single institution pilot study used autologous DRib-
ble vaccine derived from either malignant pleural effu-
sion or subcutaneous metastases, combined with GM-
CSF infusion and docetaxel in patients with NSCLC (all
patients enrolled ultimately had malignant pleural effu-
sion as the source of vaccine). Figure 1 shows the study
schema. Minimum pleural effusion volume for study eli-
gibility was 600 cm3. At least 1 × 108 tumor cells were
needed for vaccine preparation.
Eligible patients could have received up to two prior
regimens of chemotherapy for advanced NSCLC. Pa-
tients were required to have Eastern Cooperative Oncol-
ogy Group (ECOG) performance status of 2 or better, be
at least 18 years of age, capable of providing informed
consent, and have an anticipated life expectancy of at
least 6 months. Patients were required to have adequate
organ function, no untreated brain metastases, spinal
cord compression or significant co-morbidities or auto-
immune diseases, and no prior lung cancer immuno-
therapy. Prior docetaxel administration was not
excluded.
Patients with other active malignancies, known hyper-
sensitivity to docetaxel, or who were HIV, hepatitis B or
-C positive, were ineligible. Patients requiring chronic
steroids other than as replacement for adrenal insuffi-
ciency were not eligible. Patients with deterioration of
performance status beyond ECOG 2 or rapid interval
progression of disease after initial study enrollment were
not eligible to receive DRibble vaccine treatment. The
protocol was reviewed and approved by the institutional
review board at Providence Portland Medical Center,
and was conducted in accordance with the Declaration
of Helsinki. All patients provided written informed con-
sent. Funding for the study was provided by the NCI,
NIH R21 CA123864, and The Wayne D. Kuni and Joan
E. Kuni Foundation, Vancouver, WA.
Acquisition of human tumor cells and DRibble vaccine
production
Malignant pleural effusions were collected into sterile vac-
uum bottles with sodium citrate as anticoagulant. The
containers were transported on ice to the lab for vaccine
generation, and a sample was sent to pathology for con-
firmation of NSCLC. Cells were harvested by centrifuga-
tion, washed in RPMI 1640 containing gentamicin,
counted and resuspended in 1640 RPMI (Biowhitaker,
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cat# 12-702Q) containing 1.25% human albumin (ZLB
Behring LLC) and 50 μg/ml gentamicin. Tumor cells were
enumerated by light microscopy. When cells in excess of
those required for vaccine manufacture were available,
they were viably cryopreserved for use in immune func-
tion studies and attempts were made to generate tumor
cell lines. DRibble vaccine was manufactured by culturing
washed pleural effusion cells at 106 tumor cells/ml in
30 ml media containing 100 nM of bortezomib (Velcade,
Millennium Pharmaceuticals, Inc.) and 10 mM NH4Cl
(Hospira Inc., Lake Forest, IL) in a T225 cm2 flask and in-
cubated at 37 °C for 18–20 h. Culture supernatants and
cells were collected as the source of DRibbles; the cells
were lightly sonicated to release cell-bound DRibbles and
washed with HBSS (w/o Ca2+ and Mg2+, Biowhitaker,
cat# 04-315Q) at 300 x g for 10 min and the supernatant
containing DRibbles transferred to a new 50 ml conical
polypropylene centrifuge tube. The DRibbles in the super-
natant were pelleted by centrifugation at 10,000 x g for
15 min, at 4 °C. The DRibble pellet was washed with
10 ml HBSS, making sure the pellet was resuspended
thoroughly and centrifuged at 300 x g for 10 min to re-
move debris. The supernatant was centrifuged a second
time at 10,000 x g, for 15 min, at 4 °C and the pellet resus-
pended in 6% Hetastarch to attain a final DRibble concen-
tration to approximate the amount of DRibbles obtained
from 5 to 20 × 106 tumor cell equivalents / 500 ul. The
acellular DRibble preparations were irradiated with 100Gy
using a cesium irradiator (Gammacell 3000 Elan, MDS
Nordion), and were aliquotted into cryovials and frozen in
a -75 °C freezer. Sterility and endotoxin studies were
performed on final DRibble vaccine preparations, which
were stored in a monitored −80 °C freezer until use.
Characterization of DRibble vaccines
Western blots
The protein concentration for each vaccine was deter-
mined using the bicinchoninic acid (BCA) assay (Pierce).
Five replicates were performed for each sample. For pro-
tein analysis, 35 μl of DRibbles were mixed with 4X
NuPAGE LDS sample buffer and samples were resolved
by 12% SDS-PAGE (Bio-Rad). Proteins were either
stained with Coomassie or transferred to a nitrocellulose
membrane (iBlot, Invitrogen), incubated with primary
antibodies, diluted in blocking buffer (5% NFM) over-
night, and then washed and incubated with horseradish
peroxidase (HRP)–conjugated secondary antibodies for
1 h. Protein bands were revealed using chemilumines-
cent reagents (Pierce).
TLR assays
HEK-Blue cells expressing a single human TLR
(2,3,4,7,9) or NOD2 and a NF-κB/AP-1 inducible SEAP
reporter gene (Invivogen) were used to measure TLR
agonist activity in the DRibble vaccine. The Null1 cell
line with the NF-κB/AP-1 inducible SEAP reporter gene
(Invivogen) was used as a control. 10 μg DRibble vaccine
(in triplicate) was incubated with the reporter cell lines
for 16 h, after which 20 μl media was incubated with
180 μl QUANTI-Blue™ Detection media (Invivogen) for
3 h. Absorbance was measured at 600 nm on a Modulus
microplate reader (Turner BioSystems). 6% Hetastarch
Fig. 1 Study Schema
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was used as a negative control and positive controls
were used for each cell line (TLR2; LTA 500 ng/mL,
TLR3; poly (I:C) LMW 10 μg/mL, TLR4; LPS 500 pg/
mL, TLR7; CLO97 50 μg/mL, TLR9; ODN2006 10 μg/
mL, NOD2; L18-MDP 100 ng/mL).
ARIA-PMT flow cytometry
DRibbles were further characterized using antibodies
specific for CD107a (-FITC, BD Bioscience 555,800),
CD3 (-FITC, BD Bioscience 555,332), LC3 (Novus
NB600–1384) and p62/SQSTM1 (Novus NBP-48320).
Controls included mouse IgG1k-FITC (isotype control)
and normal rabbit IgG (Invitrogen) as controls for mur-
ine monoclonal antibodies or rabbit antisera respectively.
DRibbles were labeled with primary antibody at room
temperature and placed on a continuous rotator for
30 min. DRibbles were washed with 1 ml HBSS and
spun at 12,500 x g for 5 min. LC3 or p62 stained DRib-
ble preparations were then labeled with fluorescent-
conjugated antibodies and anti-rabbit-PE secondary anti-
body at 0.5 μg at room temperature on a continuous ro-
tator for 30 min in the dark. DRibbles were washed with
1 ml HBSS and spun at 12,500×g for 5 min, and resus-
pended at 50 μg/ml in FACs buffer for analysis. Analysis
of DRibbles was performed on the Becton Dickinson
(BD) Aria II with an advanced FSC PMT running BD
FacsDiva software.
Leukapheresis
After confirmation of sufficient cells for vaccine gener-
ation, but prior to initiating therapy, patients underwent
leukapheresis per standard Red Cross protocol to obtain
cells for immune monitoring. Collections were processed
by Ficoll Hypaque separation and cryopreserved in
HuAB serum and DMSO. Serum was collected and
stored at −80 °C. A second leukapheresis was scheduled
for week 12, but all patients had progressed prior to
week 12 and no post-treatment aphereses were obtained.
In addition to rapid progression, the inability to obtain
the week 12 apheresis severely limited the planned mon-
itoring of T cell immune responses.
Study therapy
Patients were treated with docetaxel 75 mg/m2 on day
one as a one-hour infusion. Premedication (including
dexamethasone) and antiemetics were administered per
institutional standard protocol. Fourteen days after doce-
taxel, patients received an initial DRibble vaccine intrader-
mally in the abdominal wall. The timing of DRibble
vaccine administration after docetaxel administration was
selected to allow for development of lymphopenia as dis-
cussed in the Background, above. The goal of the initial
docetaxel administration included tumor debulking to
allow time for the generation of an immune response to
DRibble vaccine, and augmentation of lymphocyte deple-
tion with the second dose in between vaccine administra-
tions. Vital signs were obtained every 15 min after
DRibble vaccine administration, and patients were ob-
served for adverse reactions for at least one hour after the
initial vaccine, and for at least 30 min after each subse-
quent vaccine. Vaccination sites were monitored for local
reactions 48–72 h after each vaccine administration. Con-
tinuous infusion GM-CSF was administered at the vaccin-
ation site by CADD-MS 3 pump for 6 days (50
micrograms total delivered each 24 h), starting immedi-
ately after DRibble vaccination. GM-CSF was adminis-
tered in this method to mimic the previous clinical
models in NSCLC, with the goal of enhancing the number
and function of dendritic cells at the vaccine site [23]. A
second dose of docetaxel was administered on day 29,
with DRibble vaccine and GM-CSF by continuous infu-
sion given as after the first dose. A four-week regimen of
docetaxel was selected in order to allow for a two-week
separation from vaccine administration. Eligible patients
received subsequent vaccines (accompanied by GM-CSF
infusion) every 14 days, up to a total of five vaccines. Each
vaccine was divided into a maximum volume of 0.5 cm3
for each injection, with a maximum of 7 injections per ad-
ministration. The dose of vaccine for each patient was
based upon the tumor cell yield.
Assessments
Baseline imaging for tumor measurement was performed
after thoracentesis. Follow up imaging for response as-
sessment was performed between weeks 12 to 14. Tox-
icity was reported using the Common Terminology
Criteria for Adverse Events (CTCAE) version 3.0.
Phenotype of tumor-associated lymphocytes in pleural
effusions
Cells from pleural effusions were isolated by centrifuga-
tion and cryopreserved until samples were thawed and la-
beled for flow cytometry studies. The fluorochrome-
labeled antibodies to CD4, CD8, CD19, CD14, CD45, and
CD45RO were purchased from BD Pharmingen, CD3 and
LIVE/DEAD® Fixable Yellow Dead Cell Stain Kit was pur-
chased from Invitrogen. Stained cells were analyzed on an
LSRII (BD Biosciences). Data analysis was performed
using FACSDiva (Becton Dickinson) software.
Evaluation of tumor-specific T cells in the peripheral blood
Peripheral blood mononuclear cells (PBMC) were
thawed, counted and re-suspended in X-VIVO 15
medium (Invitrogen) and plated into 24 well plates
coated with anti-CD3 (10 μg/ml, Ortho OKT-3). Two
days later, activated T cells were harvested, counted, re-
suspended at 105 cells/ml in X-VIVO15 medium con-
taining 60 IU/ml IL-2 (Prometheus) and plated into 6
Sanborn et al. Journal for ImmunoTherapy of Cancer  (2017) 5:103 Page 4 of 14
well plates for 5 to 6 days of culture in 5% CO2 at 37 °C.
Resulting effector T cells were harvested and assayed for
functional activity by measuring the release of cytokine
following 18–20 h culture with autologous tumor cells.
Controls included stimulation with allogeneic melanoma
or NSCLC cell lines, immobilized anti-CD3 (positive
control), and no stimulation (negative control). Cytokine
release was assessed using commercially available cyto-
kine ELISA or CBA kits and assays were performed ac-
cording to the manufacturers’ instructions. Samples
were assembled and evaluated in duplicate, and mean
cytokine concentration is presented (Fig. 5).
Evaluation of humoral immunity by ProtoArray
Serum samples from pre- (week 0) and the latest post-
treatment time point were profiled on ProtoArray® Hu-
man Protein Microarrays v5.0 (Invitrogen, Carlsbad, CA)
containing approximately 9000 human proteins. One
ProtoArray slide was used for each time point and slides
were processed according to the manufacturer’s instruc-
tions and scanned using an Axon GenePix 4000B fluor-
escent microarray scanner (Molecular Devices,
Sunnyvale, CA).
Protein microarray data analysis
Pixel intensities for protein location on the array were de-
termined from the GenePix Pro 6.0 software (Molecular
Devices) and analyzed using ProtoArray® Prospector 5.2.1
software (Invitrogen). Signal intensities were normalized
across arrays by quantile normalization before fold change
was determined. A minimum intensity of 1000 RFU at the
post time point was required for a response.
Statistical analysis
Due to the small number of patients in this pilot study,
statistical analysis was limited to descriptive statistics.
For the purposes of this study, antibody responses that
were increased 5-fold or greater in the post treatment
serum sample compared to baseline were considered
important.
Results
Patient characteristics
Six patients were enrolled in the study between June
2009 and September 2011, when the study was closed
due to slow accrual. Seven patients signed the informed
consent; one patient was ineligible secondary to brain
metastases requiring irradiation; six patients received
day 1 docetaxel, and 4 patients received at least one vac-
cine. Median patient age was 64 years, with a range of
54 to 81 years. Three men and three women enrolled,
each with ECOG performance status 1 on day 1. All pa-
tients had stage IV adenocarcinoma of the lung. The
average number of prior systemic therapies was one; two
patients had also received prior radiation therapy (two
treated with whole brain radiation, one patient received
palliative radiation to the eye). All patients had previ-
ously received platinum-based doublet chemotherapy,
either with paclitaxel or pemetrexed (three with bevaci-
zumab as well). Two patients had previously received a
second line of therapy (one with pemetrexed, one with
erlotinib). All patients were Caucasian. Patient charac-
teristics are summarized in Additional file 1: Table S1.
Characterization of the DRibble vaccine
The composition of the DRibble vaccine proteins varied
among the patients. All DRibble preparations contained
several putative tumor-associated antigens (Table 1).
These included Eno1 [24], LDHB [25], NPM1 [26],
PKM2 [27] and KPNA2 [28], which are commonly over-
expressed in NSCLC, are associated with poor prognosis,
and are therefore potentially relevant targets for cancer
immunotherapy. ENO1 was detected in all four DRibble
preparations. NPM1 was detected in three (Patients 2, 5,
and 6), PKM2 was detected in two (Patients 5 and 6),
while LDHB and KPNA2 were detected in one each (Pa-
tients 5 and 6, respectively). Two of these antigens
(LDHB and NPM1) have recently been reported to be
targets of humoral immunity and correlate with proteins
for which peptides could be eluted from HLA MHC
class I molecules of NSCLC cell lines [10].
Damage-associated molecular pattern molecules
(DAMPs) are an important group of sensors, inducers
and mediators of a stress response that can facilitate
antigen presentation and are associated with immuno-
genic cell death. Heat shock protein 70 (HSP70) and cal-
reticulin were two DAMPs found in all 4 DRibble
preparations, HSP90 was detected in two (Table 1). The
autophagosome-associated protein, p62, was detectable
in all vaccines.
Each of the autophagosome preparations exhibited TLR
agonist activity as depicted in Fig. 2. TLR2 activity was
evident in all, and DRibbles generated from patients 3, 5,
and 6 also expressed TLR 3 activity. DRibbles from pa-
tients 5 and 6 exhibited TLR4 agonist activity and patient
5 DRibbles also contained a functional TLR9 agonist.
Flow cytometry was used to profile the vesicles that
comprise the DRibble vaccines. Autologous DRibbles
from pleural effusions were compared to DRibbles made
from the UbiLT3 cell line (Fig. 3). DRibbles were labeled
with antibodies specific for the autophagosome marker
LC3, the autophagosome-associated protein p62, and the
lysosome and autolysosome marker LAMP1. An anti-
body specific for CD3 was used as a control for non-
specific binding. DRibbles from patient 2 were highly
auto-fluorescent in the fluorescein isothiocyanate (FITC)
channel with low specific LC3, p62, or LAMP1 staining.
DRibbles from patients 3, 5, and 6 contained vesicles
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positive for LC3 (30.8–50.1%) and p62 (22.9–37.4%),
showing that DRibble preparations contained autopha-
gosomes. LAMP1 staining was highest in the DRibbles
from patient 5 (22.4% LAMP1 + LC3-, 26.3% LAMP1 +
LC3+, 33.7% LAMP1 + p62-, 14.7% LAMP1 + p62+),
while patients 3 and 6 had more vesicles that were LC3+
and p62+, but LAMP1-. These data indicate that while
the composition of autologous DRibbles can vary from
sample to sample, they all contain autophagosomes and
autolysosomes, the novel antigenic cargo carriers that
DRibbles are posited to deliver.
Treatment
All six eligible patients underwent baseline leukapher-
esis, and received day 1 docetaxel (see CONSORT dia-
gram, Additional file 2: Figure S1). Five patients received
full-dose docetaxel on day 1 (75 mg/m2), while one pa-
tient required initial dose reduction due to abnormal
liver function tests (60 mg/m2). Only four patients re-
ceived the first dose of DRibbles as planned on day 15.
All four of those patients completed their GM-CSF infu-
sions and received the day 29 dose of docetaxel, the day
43 DRibble vaccine, and GM-CSF. One patient required
a one-week treatment delay due to pneumonia.
Two patients were able to receive the day 57 DRibble
vaccine and GM-CSF. One patient received the day 71
vaccine and GM-CSF; however, no patient underwent a
second leukapheresis at week 12 as initially planned.
Overall, two patients did not receive vaccine, two pa-
tients received 2 vaccines each, one patient received
three, and one patient received four vaccines.
Finding patients eligible for this study was difficult, and
the study ultimately was halted due to slow accrual. The
primary limitation was the identification of patients with
malignant pleural effusions whose performance status was
adequate both for study eligibility and to allow time for
DRibble preparation (17 days from the time of pleural fluid
collection until the completion of sterility testing after vac-
cine generation). Furthermore, the ability to administer
DRibbles to patients serially was hampered by rapid clin-
ical progression in this poor-prognosis population.
Toxicity
Adverse events are shown in Tables 2 and 3. The majority
were Grade 1 or 2 events (37 events; 57%), with 27 Grade
3 or 4 events reported (41.5% of total). Two Grade 5
events were reported: neutropenic fever/sepsis in a patient
who did not receive a DRibble vaccine, and respiratory
failure in a patient with pneumonia who received 2 doses
of docetaxel and two DRibble vaccines. Adverse events
were attributed primarily to docetaxel or underlying dis-
ease progression. The administration of DRibbles was well
tolerated, with only one toxicity attributed to DRibble vac-
cine, a Grade 1 injection site reaction.
Table 1 Characteristics of DRibble preparations
Antigensa DAMPs
Patient ID Tumor # # vac given Tumor Cell Eq/vaccine ∝g Protein/vaccine P62 NPM1 KPNA2 LDHB ENO1 PKM2 HSP90 HSP70 CALR
Patient 2 LT80 2 1.32E + 07 730 ++ +++ ND ND +++ ND + + +++
Patient 3 LT79 3 1.65E + 07 125 + ND ND ND +++ ND ND +++ +
Patient 5 LT84 4 2.10E + 07 560 +++ + ND +++ + + ND +++ +
Patient 6 LT96 2 4.00E + 07 480 +++ +++ + ND +++ +++ + +++ +++
DRibble vaccine was produced from autologous tumor and protein content was determined by the bicinchoninic acid assay (BCA). Proteins were identified by
Western Blot and assigned plus symbols based on intensity of the blot (NPM1 nucleophosmin, KPNA2 karyopherin alpha 2, LDHB lactate dehydrogenase B, ENO1
enolase 1); PKM2 pyruvate kinase isozymes M1/M2, HSP Heat-shock protein, CALR Calreticulin. ND: Not Determined. aAntigens detected by Western blot
Fig. 2 LR agonist activity of patient-derived autologous DRibbles. HEKBlue reporter cell lines (TLR2, TLR3, TLR4, TLR7, TLR9, NOD2 and control cell
line Null1) were incubated with 20ìl autologous DRibbles (Patient 2, Patient 3, Patient 5, Patient 6) (in triplicate) for 16 hrs. SEAP secretion in the
media was measured in Quanti-Blue media by absorbance at 600nm and compared to cell line specific positive controls
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Grade 3/4 hematologic toxicities (12 events; 44.4%) in-
cluded leukopenia, lymphopenia, neutropenia, and
anemia. One episode of grade 3 febrile neutropenia was
reported, with the patient subsequently continuing on
study therapy. The majority of the Grade 3/4 events
were non-hematologic (55.6%; 15 events); seven events
were due to pulmonary symptoms (dyspnea, hypoxia,
cough, pneumonia, respiratory failure).
Two patients died during therapy, neither of whom re-
ceived a DRibble vaccine; one developed altered mental
status on day 11 after chemotherapy (attributed to doce-
taxel), had progressive functional decline, and was dis-
charged to hospice, and the other was admitted to
hospital on day 4 after docetaxel with hyponatremia,
subsequently developed neutropenic fever with sepsis,
and expired due to metastatic lung cancer and sepsis.
Efficacy
No patient remained on study at the time of planned
disease assessment at Day 85. At this time all six pa-
tients had discontinued therapy because of disease
progression, and three had died. One patient under-
went early disease assessment because of symptoms
of tumor progression, and progressive disease was
confirmed at Day 44. All patients are deceased. Me-
dian survival from Day 1 of treatment was five
months (range 11 days-16 months). No patient re-
ceived subsequent anticancer therapy.
Fig. 3 Phenotype of autologous DRibbles derived from pleural effusions compared to DRibbles from the NSCLC cell line UbiLT3.
Autophagosomeenriched DRibbles for patients 2, 3, 5, 6, and UbiLT3 DRibbles, derived from a lung tumor cell line, used as a control, were
labeled with autophagosome specific antibodies [anti-LC3 (PE), anti-LC3 (PE)/LAMP1-FITC, anti-p62 (PE), or anti-p62 (PE)/LAMP1-FITC]. Normal
rabbit IgG (isotype control; i.c.) and CD3-PE were used as controls. Patient-derived DRibble preparations were more heterogeneous compared
with cell-line derived UbiLT3
Table 2 Hematologic Toxicities
Toxicity Grade 1
N (%)
Grade 2
N (%)
Grade 3
N (%)
Grade 4
N (%)
Grade 5
Anemia 1 (16.7%)
Febrile
Neutropenia/Sepsis
1 (16.7%) 1 (16.7%)
Leukopenia 1 (16.7%) 2 (33.3%) 1 (16.7%)
Lymphopenia 3 (50%) 4 (66.7%) 3 (50%)
Neutropenia 2 (33.3%) 2 (33.3%)
Hematologic toxicities were attributed to docetaxel, not DRibble vaccine
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Characterization of the immune cells in pleural fluid
Based on light scatter properties and the absence of
CD45, we estimated that tumor cells comprised from
4%–14% of viable cells in the pleural effusions (Fig. 4).
Immune cells comprised the majority of cells detected in
the pleural effusions, with similar profiles in 3 (patients
3, 5 and 6) of 4 patients (Fig. 4). Antigen-experienced
memory and effector cells (CD45RO+) comprised the
majority of CD4 (74–84%) and CD8+ (59–61%) T cells
contained in the pleural fluid from patients 3, 5 and 6,
while only 36% of CD8+ T cells from patient 2 were
CD45RO+ (data not shown).
T cell responses to autologous tumor cells
Patients’ PBMCs were expanded as specified in the
methods and co-cultured with autologous tumor cells
(when available) or control allogeneic tumor cells in an
attempt to detect tumor-specific reactivity. This was the
case for tumors from patients 3, 5 and 6. For patient 2
there were only sufficient tumor cells to manufacture
the vaccine. Among the three patients with autologous
tumor cells available for this assay (patients 3, 5, and 6),
patient 6 had PBMC only available following a single
vaccine (Day 43) and no IFN-γ response was detected
against his autologous tumor cells (data not shown). Of
the two patients (3 and 5) who were evaluable 14 days
following their second (patient 3, D57) or third and
fourth vaccine (patient 5, D71 and D85), both developed
new or augmented cytokine responses to autologous
tumor cells (Fig. 5). Patient 3, who demonstrated a
strong (>3000 pg) pre-existing IFN-γ response, devel-
oped a strong (>2000 pg) tumor-specific IL-5 response.
Patient 5, the only patient evaluable 14 days after their
third vaccination (D71), demonstrated a vaccine-induced
increase in tumor-specific secretion of IFN-γ and TNF-α
that was respectively 2-fold and 6-fold higher than base-
line. Interestingly, this patient also exhibited an increase
over pre-existing baseline tumor-specific IL-5 and IL-10
cytokine responses (Fig. 5). The decline in tumor-
specific cytokine secretion for patient 5 by day 85 coin-
cided with the detection of tumor progression. Given
that no patient underwent week 12 leukapheresis, fur-
ther immune evaluation was limited.
Evaluation of humoral immune responses
Given the difficulty of discerning which epitopes were
recognized by patients’ T cells following administration
of a complex autologous tumor cell-derived vaccine, we
hypothesized that humoral responses would provide
clues both to the breadth and specificity of the T cell re-
sponse. While data are limited, this concept is supported
by several authors who used humoral immune responses
to identify T cell responses in patients with prostate and
NSCLC [29, 10]. Serum IgG antibody responses, which
Table 3 Non-hematologic Toxicities
Toxicity Grade 1
N (%)
Grade 2
N (%)
Grade 3
N (%)
Grade 4
N (%)
Grade 5
N (%)
Dyspnea 2 (33.3%) 2 (33.3%) 1 (16.7%)
Respiratory
Failure
1 (16.7%) 1 (16.7%)
Upper
Respiratory
Infection
1 (16.7%)
Cough 1 (16.7%) 1 (16.7%)
Pneumonia 1 (16.7%)
Hallucinations 1 (16.7%)
Dehydration 1 (16.7%) 1 (16.7%)
Hypotension 1 (16.7%) 1 (16.7%)
Dermatology,
Other
(Heating
pad burn)
1 (16.7%)
Pain 1 (16.7%) 1 (16.7%) 1 (16.7%)
Peripheral
Neuropathy
1 (16.7%)
Hyperglycemia 1 (16.7%)
Infection 1 (16.7%)
Sore throat 1 (16.7%)
Flu-like
symptoms
1 (16.7%)
Fatigue 1 (16.7%) 4 (66.7%)
Arthralgia 1 (16.7%)
Headache 1 (16.7%)
Fever 2 (33.3%)
Decreased
level of
consciousness
1 (16.7%)
Nausea/
Vomiting
1 (16.7%)
Hyponatremia 1 (16.7%)
Hypoxia 1 (16.7%)
Syncope 1 (16.7%)
Rash 1 (16.7%)
Injection
site reactiona
1 (16.7%)
Infection,
Other (Lip)b
1 (16.7%)
Dizziness 1 (16.7%)
Constipation 1 (16.7%)
Hypoalbuminemia 1 (16.7%)
aAttributed to DRibble vaccine
bAttributed as unlikely related to DRibble vaccine
All other toxicities were attributed as unrelated to DRibble vaccine, but were
considered related to docetaxel or underlying disease
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require antigen-specific CD4 T cell help, were assessed
before and after vaccination in day 71 sera in patients 3
and 5. Samples for patient 2 and 6 were assessed at base-
line and day 43 or 45. Patients 2, 3, 5 and 6 had 16, 18,
4 and 11 increased (>5 fold) antibody responses, respect-
ively. Patient 2 made strong 5× antibody responses to 16
proteins (ZADH2, RRAGB, PFN2, RIMS3, C7orf62,
GPM6A, MED9, FRG1BP, RPS6KB1, ETV4, ABL1,
ZAP70, SPRR2G, SF3A3, PIM2, and RCHY1), patient 3
responded to 18 proteins (HIC2, AKT1S1, NPM1, cDNA
clone IMAGE:5,271,031, ALOXE3, MAD2L1, RPS6KB1,
MKNK1, BPHL, SLC29A1, DNAJB1, SNAPAP, EIF2B2,
RRAGB, LIMK1, DNAJC5, ZC3HAV1L and NDUFB6),
patient 5 had strong antibody responses against 4 pro-
teins (LRSAM1, GPM6A, PLK2 and IMPA2) and patient
6 had antibody responses against 11 proteins (SMAD3,
ARHGEF16, NOC2L, SMAD2, EIF5, ATF1, C7orf28B,
NME7, DTNBP1, ERBB2 and EPHB4).
We investigated whether the strong antibody responses
produced by different patients recognized any of the same
proteins. Among the proteins to which strong antibody re-
sponses were made, none were recognized by antibodies
in all four patients (Fig. 6). Patients 2 and 3 both made re-
sponses to ribosomal protein S6 kinase, 70 kDa, polypep-
tide 1 (RPS6KB1), which is overexpressed or amplified in
19% of TCGA lung adenocarcinoma samples (provisional
database, as of June 2017) and 10% of squamous cell lung
cancer samples (provisional database; as of June 2017).
The other shared 5× responses are glycoprotein M6A
(GPM6A) (patients 2 and 5) and Ras-related GTP binding
B (RRAGB), transcript variant RAGBl (patients 2 and 3).
Interestingly, the proteins targeted by the strong antibody
responses are products of genes noted to have an amplifi-
cation, mRNA upregulation or mutation in patients with
adenocarcinoma of the lung (LUAD database, TCGA).
This opens the possibility that these strong antibody re-
sponses and the associated CD4 T cell responses against
the same protein that are required for IgG class-switching
could be targeting antigens relevant for these patients.
Additional support for the relevance of immune responses
against these proteins is a recent report that peptides from
two of the proteins targeted by an antibody response in
patient 3 (NPM1 and NDUFB6) were reported to be pre-
sented by HLA class I of NSCLC cell lines [10].
Discussion
Our group has a long-standing interest in autologous
tumor cell vaccines that is grounded in the preclinical
work of Prehn and Main, who documented that whole
cell vaccines were most effective at providing protection
from a tumor challenge with the same tumor cells com-
prising the vaccine [30]. Vaccines derived from different
tumors of the same histology, induced by the same car-
cinogen, were not effective. One explanation was that
unique tumor-specific rejection antigens were present in
each independently-derived tumor. In our previous pilot
study of autologous NSCLC vaccines genetically modi-
fied to express GM-CSF, survival was increased in the
cohort of patients whose vaccines made >40 ng GM-
CSF/106 cells/24 h [31]. This approach was limited by
the requirement for surgery in stage IV patients to ob-
tain tissue to prepare the vaccines. In a follow-up study,
Fig. 4 The immune cells contained in the pleural effusion were
examined by flow cytometry. Phenotype was determined by
staining with anti-CD45 and lineage-specific markers. Tumor cells
were identified by light scatter characteristics and defined as live
cells without the CD45 and lineage-specific markers. Pie charts
depict percentages of live cells detected in pleural effusions for each
of the patients. Phenotypes represented are CD14+ monocytes
(blue), CD19+ B cells (red), CD4+ T cells (green), CD8+ T cells
(purple), other leukocytes (light blue) and tumor cells (tan)
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autologous tumor cells were mixed with a bystander cell
line (K562) engineered to secrete GM-CSF. This strategy
failed to improve patient survival [22].
Immunotherapy with checkpoint blockade for lung
cancer has demonstrated significant efficacy in a
small proportion of patients, with checkpoint inhibi-
tors now approved for patients with advanced NSCLC
[32–35]. Although nivolumab has demonstrated un-
precedented long-term survival in a few heavily-
pretreated patients with NSCLC, with three-year
overall survival reaching 18% in a phase I study [36],
only a minority of patients experience this longer-
term benefit. Long-term overall survival data is not
yet available for pembrolizumab in patients with
previously-untreated advanced NSCLC with >50%
tumor PD-L1 expression. Although pembrolizumab is
FDA-approved as a single agent in this setting, as
well as in combination with carboplatin and peme-
trexed for advanced non-squamous NSCLC regardless
of PD-L1 status based upon superior progression-free
survival and response rates compared with chemo-
therapy (4 month improvement in progression-free
survival compared with chemotherapy), only 45% of
patients with single agent, and 55% of patients receiv-
ing the triplet combination, experience disease re-
sponse [37, 38]. Strategies that increase immune
recognition and immune control are needed. Combin-
ation of anti-PD1 and anti-CTLA-4 inhibitors
Fig. 5 Effector T cells generated from PBMC were cultured alone or with allogeneic or autologous tumor cells and cytokine secretion was
measured. PBMC from Patients 3 (a) and 5 (b) were collected at times specified in the figure legend. T cells were then cultured either alone
(none), with allogeneic tumor cells (LT-60), or with the autologous tumor cells, LT-79 and LT-84 for patients 3 and 5 respectively. After 18-20
hours of culture, supernatants were collected and the concentration of cytokine, specified in the legend, were measured
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demonstrated superior response rates compared with
monotherapy in advanced melanoma [39], as well as
in advanced NSCLC in a few early phase trials, with
ongoing cohort expansion and phase III trials for
confirmation of activity pending [40, 41].
This trial, which was performed before the efficacy of
checkpoint blockade had been demonstrated, investi-
gated a novel autologous vaccine containing multiple
specific tumor-associated antigens created from short-
lived proteins (SLiPs) and defective ribosomal products
(DRiPs) packaged in a double membrane microvesicle.
We hypothesize that a major benefit of the DRibble vac-
cine strategy is the increased presentation of multiple
overexpressed antigens that are not normally available
for cross-presentation because they are short-lived [42].
This autologous DRibble vaccine, generated from cells
collected from malignant pleural effusions in patients
with NSCLC, generated an IgG antibody response
against multiple discrete proteins in the four patients
evaluable for humoral immune responses. As the gener-
ation of an IgG antibody response requires CD4 T cell
help for switching antibody class from IgM to IgG, we
hypothesize that the development of IgG antibody re-
sponses is a surrogate for the generation of a CD4 T cell
response against the same antigen. Interestingly, with
this personalized tumor vaccine approach, each patient
generated an immune response against antigens that
were unique to the individual. While an immune re-
sponse against multiple antigens was induced or
boosted, this immune response was still ineffective in
controlling the cancer.
We postulate that effective control of cancer will
require induction of immunity against a spectrum of
cancer antigens, administration of a T cell agonist to
boost that immunity and an inhibitor of immune
checkpoints to overcome cancer escape mechanisms.
We also consider the biggest hurdle for successful im-
munotherapy is the ability to generate immunity
against a spectrum of cancer antigens and have evalu-
ated this autologous DRibble vaccine strategy as an
approach to induce that immunity. Many of the IgG
antibody responses that developed or were augmented
by vaccination were against proteins whose genes
were shown by TCGA analyses to be commonly over-
expressed in NSCLC, making them possible targets
for an anti-cancer immune response.
While the library of peptides that are presented by
HLA on the surface of cancer cells is not well studied
[43], a recent paper reported that a large number of
antibody responses in patients with NSCLC were di-
rected against proteins whose peptides were presented
by HLA of NSCLC cell lines [10]. They went on to re-
port that presence of an antibody response correlated
with the detection of cytotoxic T cell response against
HLA-matched NSCLC cell lines. Consistent with that
observation, our group recently reported that the detec-
tion of an IgG response following vaccination with a
DRibble vaccine, in a preclinical model of breast cancer,
correlated with the development of a CD8 T cell re-
sponse to the same peptide and to the specific mammary
cancer cell line [44].
The protoArray data from the current study suggests
that CD4 T cells, and hypothetically a coordinated CD8
T cell response, were induced or boosted against a num-
ber of proteins whose genes are over-expressed by
NSCLC, however, only 1 patient had PBMC and autolo-
gous tumor cells available to assess anti-cancer immun-
ity 14 days following their 3rd or 4th vaccination. That
this patient developed an increased autologous tumor-
specific responses of both type 1 and type 2 cytokines
may not be optimal, but it provides insight into modifi-
cations to the composition of the vaccine that may fur-
ther skew strong type 1 cytokines without augmenting
type 2 cytokine responses. Additionally, it is thought-
provoking that the cytokine response of patient 5 dimin-
ished at the time when the patient experienced progres-
sion (D85). This fluctuation may have been the result of
tumor progression shutting off the immune response, or
it may be the result of T cell contraction, a natural com-
ponent of a T cell response to antigen [45].
We hypothesize that contraction explains the fluctu-
ation in TCR clones we detected in patients receiving an
allogeneic DRibble vaccine as adjuvant therapy for
NSCLC [46]. This highlights the possibility of combining
vaccines with T cell agonists that blunt contraction by
Fig. 6 Increased antibody responses after vaccination. Serum from
pre-treatment and day 71 (patients 2, 3 and 5) or day 43 (patient 6)
was assessed for antibody responses against 9,000 human proteins.
After data filtering, the number of antibodies with a greater than 5
-fold increase (with a minimum RFU value > 1000 post vaccination)
for each patient were calculated and presented above in a Venn
diagram, with shared humoral responses represented within
overlapping sections
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augmenting T cell expansion and sustaining antigen-
specific T cells [47, 48]. Strategies that monitor expan-
sion and survival of T cell clones may be useful in sort-
ing out the contribution of agents in combination
immunotherapy trials which contain cancer vaccines.
Development of methods to evaluate contributions of in-
dividual agents in combination immunotherapy trials
was recently identified as an objective by the US FDA
[49]. This is particularly true for the development of T
cell agonists, where the receptor is only expressed on
the responding T cell for a few days following activation.
While preclinical studies have documented that combin-
ing cancer vaccines with T cell agonists can increase the
therapeutic effect [50–55], their application in the clinic
is yet to be reported.
Vaccine strategies for lung cancer, as for most solid tu-
mors, have failed to make a significant impact on sur-
vival as monotherapy, even though there is evidence of
vaccine-induced anti-cancer immunity [56, 57]. A recent
meta-analysis of 18 randomized clinical trials evaluating
tumor vaccines and cellular immune therapies in
NSCLC reported an average overall survival benefit of
5.4 months (in addition to progression free survival
benefit), despite the lack of benefit in the individual
studies [58]. The observation that DRibble vaccination
was safe and was associated with the development of im-
mune responses against putative cancer-associated anti-
gens in this population of patients with advanced disease
is interesting, and would support the concept of combin-
ing this strategy with additional immune intervention
and evaluating its potential value in earlier stage pa-
tients. In addition to checkpoint blockade, costimulatory
antibodies have antitumor activity in several models and
have significantly augmented therapeutic efficacy of
DRibble vaccine in several preclinical models [54, 55].
Given the advanced stage of the patients in this
trial, it is not a surprise that a vaccine failed to con-
trol tumor growth, and is consistent with the results
reported from previous individual vaccine trials in
similar patient populations. The ability to assess the
value of DRibble vaccination was severely limited by
the inability of adequate numbers of patients to
complete the entire treatment regimen. Completion
of the study was hampered by slow accrual, which
was the direct consequence of the generally poor per-
formance status of patients with previously-treated
NSCLC who had a malignant pleural effusion suitable
for vaccine generation, as well as the time required
to make the DRibble preparation in the setting of
progressive disease. Evaluation of long-term vaccine
administration, disease response, and comparison with
immune response was impaired by the rapid clinical
decline and short survival of the patient population
treated, rendering the investigational plan infeasible.
As a next step, our institution is now investigating an
allogeneic DRibble vaccine, generated from two estab-
lished cancer cell lines, in patients with locally-
advanced NSCLC.
Conclusions
Administration of a novel autologous DRibble vaccine in
patients with advanced NSCLC was safe in the small
population of patients tested. Immune responses against
putative cancer-associated antigens were demonstrated
in thissmall sample of patients, but further assessment
in this study population was infeasible due to their poor
prognosis and rapid clinical decline. Further investiga-
tion has moved forward with an allogeneic DRibble vac-
cine for patients with locally-advanced NSCLC.
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